Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renoral is a protein-based dietary supplement and nutritional solution developed by the Paris-based company Indigo Therapeutics for the management of patients with renal insufficiency, specifically those with end-stage renal disease (ESRD) undergoing hemodialysis. Formulated as a ready-to-use drink containing native proteins, Renoral is positioned within the field of microbiotherapy. It is designed to provide intradialytic compensation for amino acid losses that occur during the dialysis process, serving as an oral alternative to intravenous amino acid supplementation. Clinical studies have evaluated Renoral by comparing its intradialytic plasma kinetics of amino acids against standard intravenous treatments such as Aminoven.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renoral (INDIGO Biosciences).